AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Share Issue/Capital Change Jan 15, 2013

7612_rns_2013-01-15_ebe20bde-2515-4fbb-b9c0-119d37cb42a1.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

ECO Animal Health Group plc (ECO)

(AIM:EAH)

Issue of Equity and Director Dealing

The Company announces that certain employees and directors have exercised an aggregate of 59,640 options in the Company.

The details of the options exercised by the directors are as follows:

Director name No. of options Exercise price
Marc Loomes 8,000 £1.085
Brett Clemo 16,000 £1.085
Julia Trouse 7,640 £1.085

The 59,640 ordinary shares have been sold by the relevant employees and directors and been purchased by Peter Lawrence at an average price of 240 pence per ordinary share.

Accordingly the directors’ shareholdings remain unchanged following this transaction except for Peter Lawrence who has an interest in 11,268,176 ordinary shares representing 20.36% of the Company’s issued share capital.

Application has been made for the admittance to trading of 59,640 ordinary shares in the Company as a result of this exercise of options. It is anticipated that these shares will be admitted to trading on 18 January 2013.

Following the admittance to trading of the 59,640 ordinary shares, total number of ordinary shares in issue will be 55,337,516 .

Contacts:

ECO Animal Health Group plc
Peter Lawrence 020 8336 6190
Spiro Financial
Anthony Spiro 020 8336 6196
Cenkos Securities plc (Nominated Adviser)
Stephen Keys 020 7397 8926

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Talk to a Data Expert

Have a question? We'll get back to you promptly.